Breast Cancer
Pfizer Sutent (6488)
A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Maleate (Sutent) in Combination With Weekly Paclitaxel (Taxol) Followed by Doxorubicin (Adriamycin) and Daily Oral Cyclophosphamide (Cytoxan) Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer
Investigator: Jennifer Specht, MD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT00513695
A Phase III Randomized, Multicenter, Two-Arm, Open-Label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2 Positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy
Investigator: V.K. Gadi, MD, PhD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT01419197
Phase III Randomized Trial of the Effect of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Investigator: Fred Appelbaum, MD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT01101438
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab (Herceptin) in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Investigator: Tanya Wahl, MD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT01275677
A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) With or Without Bevacizumab, Either Preceded by or Followed By Q 2 Week Doxorubicin (A) and Cyclophosphamide (C) Plus Pegfilgrastim (PEG-G) As Neoadjuvant Therapy for Inflammatory and Locally Advanced Her-2/Neu Negative Breast Cancer
Investigator: Fred Appelbaum, MD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT00856492
Phase I-II Study of HER2 Vaccination with poly(I) Poly(C12U) (Ampligen®) as an Adjuvant in Optimally Treated Breast Cancer Patients
Investigator: Lupe Salazar, MD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT01355393
A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment
Investigator: Frederick Appelbaum, MD; Conditions: Breast Cancer; Status: Recruiting; Study ID: NCT00382018
Imaging Early Response of ER+, HER2- Breast Cancer To Aromatase Inhibitor (AI) Therapy
Investigator: David Mankoff, M.D., PhD ; Conditions: Breast Cancer; Status: Recruiting
A Phase III clinical trial of Accelerated Whole Breast Irradiation with Hypofractionation plus concurrent boost versus standard Whole Breast Irradiation plus sequential boost for early-stage breast cancer.
Investigator: George Laramore, MD; Conditions: Breast cancer; Status: Recruiting; Study ID: NCT01349322
Join Us On